Literatur

[1] Leitlinienprogramm Onkologie S3-Leitlinie Supportive Therapie April 2017 S. 96-127
[2] Roila F et al. Support Care Cancer 2016, Aug 11 [Epub ahead of print]
[3] Herrstedt J et al. Support Care Cancer 2016, Jul 22 [Epub ahead of print]
[4] Casper J. et al. Richtlinien zur antiemetischen Therapie. In: Schmoll HJ Kompendium internistische Onkologie Springer 1999 S. 1489-1511
[5] Diemunsch P et al. Drugs 2000;60:533-546
[6] Grunberg SM et al. N Engl J Med 1993;329: 1790-1796
[7] Hornby PJ Am J Physiol Gastrointest Liver Physiol 2001;280: G1055-G1066
[8] Navari R.N. et al N Engl J Med 2016;374:1356-67
[9] Grunberg SM et al. Cancer. 2004;100:2261-8
[10] Basch E. NEJM 2010;362(10):865-9
[11] Di Maio M et al. JCO,  2015; 33:910-915
[12] Lorusso V et al. Support Care Cancer 2009;17(12):1469-73
[13] MASCC: Supportive Care in Cancer (Vol. 27, Supplement 5, 2016) www.mascc.org/antiemetic-guidelines
[14] ESMO: Ann Oncol (2016) 27 (suppl 5): v119-v133 www.esmo.org/Guidelines/Supportive-and-Palliative-Care/MASCC-and-ESMO-Consensus-Guidelines-for-the-Prevention-of-Chemotherapy-and-Radiotherapy-Induced-Nausea-and-Vomiting
[15] Martin M. Oncology 1996; 53(Suppl 1): 26 – 31